The content on this site is intended for healthcare professionals only
Dr Luis Raez reviews four key lung cancer presentations from WCLC 2026, highlighting emerging antibody drug conjugates for small cell lung cancer, new targeted therapies for ROS1 positive NSCLC, and first line treatment developments for EGFR exon 20 insertion NSCLC.
| Tam-Peli, an anti-B7-H3 antibody-drug conjugate, versus topotecan in relapsed SCLC: A randomized, open-label, phase 3 study (TAISHAN-302) | |
| Risvutatug rezetecan (a B7-H3-Directed ADC) versus topotecan in relapsed SCLC: Primary results of phase 3 ARTEMIS-008 | |
| Zidesamtinib in TKI-naive patients with advanced/metastatic ROS1+ NSCLC: ARROS-1 efficacy and safety data | |
| Zipalertinib plus chemotherapy for 1st line NSCLC with EGFR exon 20 Insertions: Results from the phase 3 REZILIENT3 trial |
Triplet regimen of amivantamab, lazertinib, and pemetrexed showed robust efficacy in advanced EGFR-mNSCLC
Concurrent thoracic radiotherapy plus chemo-ICI shows no overall survival benefit in ES-SCLC
Tarlatamab improves brain metastases control and survival compared to chemo in SCLC
Denikitug shows immune activation and early anti-tumour activity in advanced solid tumour
TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance
Cracking the code: Bispecific immunotherapy in small cell lung cancer
Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC
Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
